Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro

Takashi Morisaki, Masayo Umebayashi, Akifumi Kiyota, Norihiro Koya, Hiroto Tanaka, Hideya Ohnishi, Mitsuo Katano

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: We explored the possibility of combining adoptive immunotherapy with cytokine-activated killer (CAK) cells and the epidermal growth factor receptor monoclonal antibody, cetuximab, as a treatment for cholangiocarcinoma. Materials and Methods: CAK cells were cultured with a highdose of interleukin-2 and anti-CD3 monoclonal antibodies. This cell population contained both activated CD16+/CD56+ (NK) cells and CD3+/NKG2Dhigh+ T-cells. The effect of CAK cells and cetuximab, alone and in combination, on the viability of human cholangiocarcinoma cells was evaluated. Results: Culture of CAK cells alone, but not cetuximab alone, exhibited modest cytotoxicity toward cholangiocarcinoma cells. However, combining CAK cells with cetuximab significantly enhanced cytotoxicity. This enhancement was inhibited by the addition of excess human immunoglobulins, suggesting that antibody-dependent cytotoxicity, mediated by activated NK cells in the CAK cell culture was involved in this mechanism. Conclusion: Cetuximab may be used to enhance CAK cell therapeutic activity in patients with cholangiocarcinoma, by potentiating antibody-dependent cellular cytotoxicity.

Original languageEnglish
Pages (from-to)2249-2256
Number of pages8
JournalAnticancer Research
Volume32
Issue number6
Publication statusPublished - Jun 2012

Fingerprint

Cholangiocarcinoma
Lymphocytes
Cytokines
Natural Killer Cells
Monoclonal Antibodies
Adoptive Immunotherapy
Cetuximab
In Vitro Techniques
Antibodies
Epidermal Growth Factor Receptor
Interleukin-2
Immunoglobulins
Cultured Cells
Cell Culture Techniques
T-Lymphocytes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Morisaki, T., Umebayashi, M., Kiyota, A., Koya, N., Tanaka, H., Ohnishi, H., & Katano, M. (2012). Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. Anticancer Research, 32(6), 2249-2256.

Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. / Morisaki, Takashi; Umebayashi, Masayo; Kiyota, Akifumi; Koya, Norihiro; Tanaka, Hiroto; Ohnishi, Hideya; Katano, Mitsuo.

In: Anticancer Research, Vol. 32, No. 6, 06.2012, p. 2249-2256.

Research output: Contribution to journalArticle

Morisaki, T, Umebayashi, M, Kiyota, A, Koya, N, Tanaka, H, Ohnishi, H & Katano, M 2012, 'Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro', Anticancer Research, vol. 32, no. 6, pp. 2249-2256.
Morisaki, Takashi ; Umebayashi, Masayo ; Kiyota, Akifumi ; Koya, Norihiro ; Tanaka, Hiroto ; Ohnishi, Hideya ; Katano, Mitsuo. / Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. In: Anticancer Research. 2012 ; Vol. 32, No. 6. pp. 2249-2256.
@article{1bd2726229e1484397007c34d5b61b01,
title = "Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro",
abstract = "Aim: We explored the possibility of combining adoptive immunotherapy with cytokine-activated killer (CAK) cells and the epidermal growth factor receptor monoclonal antibody, cetuximab, as a treatment for cholangiocarcinoma. Materials and Methods: CAK cells were cultured with a highdose of interleukin-2 and anti-CD3 monoclonal antibodies. This cell population contained both activated CD16+/CD56+ (NK) cells and CD3+/NKG2Dhigh+ T-cells. The effect of CAK cells and cetuximab, alone and in combination, on the viability of human cholangiocarcinoma cells was evaluated. Results: Culture of CAK cells alone, but not cetuximab alone, exhibited modest cytotoxicity toward cholangiocarcinoma cells. However, combining CAK cells with cetuximab significantly enhanced cytotoxicity. This enhancement was inhibited by the addition of excess human immunoglobulins, suggesting that antibody-dependent cytotoxicity, mediated by activated NK cells in the CAK cell culture was involved in this mechanism. Conclusion: Cetuximab may be used to enhance CAK cell therapeutic activity in patients with cholangiocarcinoma, by potentiating antibody-dependent cellular cytotoxicity.",
author = "Takashi Morisaki and Masayo Umebayashi and Akifumi Kiyota and Norihiro Koya and Hiroto Tanaka and Hideya Ohnishi and Mitsuo Katano",
year = "2012",
month = "6",
language = "English",
volume = "32",
pages = "2249--2256",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro

AU - Morisaki, Takashi

AU - Umebayashi, Masayo

AU - Kiyota, Akifumi

AU - Koya, Norihiro

AU - Tanaka, Hiroto

AU - Ohnishi, Hideya

AU - Katano, Mitsuo

PY - 2012/6

Y1 - 2012/6

N2 - Aim: We explored the possibility of combining adoptive immunotherapy with cytokine-activated killer (CAK) cells and the epidermal growth factor receptor monoclonal antibody, cetuximab, as a treatment for cholangiocarcinoma. Materials and Methods: CAK cells were cultured with a highdose of interleukin-2 and anti-CD3 monoclonal antibodies. This cell population contained both activated CD16+/CD56+ (NK) cells and CD3+/NKG2Dhigh+ T-cells. The effect of CAK cells and cetuximab, alone and in combination, on the viability of human cholangiocarcinoma cells was evaluated. Results: Culture of CAK cells alone, but not cetuximab alone, exhibited modest cytotoxicity toward cholangiocarcinoma cells. However, combining CAK cells with cetuximab significantly enhanced cytotoxicity. This enhancement was inhibited by the addition of excess human immunoglobulins, suggesting that antibody-dependent cytotoxicity, mediated by activated NK cells in the CAK cell culture was involved in this mechanism. Conclusion: Cetuximab may be used to enhance CAK cell therapeutic activity in patients with cholangiocarcinoma, by potentiating antibody-dependent cellular cytotoxicity.

AB - Aim: We explored the possibility of combining adoptive immunotherapy with cytokine-activated killer (CAK) cells and the epidermal growth factor receptor monoclonal antibody, cetuximab, as a treatment for cholangiocarcinoma. Materials and Methods: CAK cells were cultured with a highdose of interleukin-2 and anti-CD3 monoclonal antibodies. This cell population contained both activated CD16+/CD56+ (NK) cells and CD3+/NKG2Dhigh+ T-cells. The effect of CAK cells and cetuximab, alone and in combination, on the viability of human cholangiocarcinoma cells was evaluated. Results: Culture of CAK cells alone, but not cetuximab alone, exhibited modest cytotoxicity toward cholangiocarcinoma cells. However, combining CAK cells with cetuximab significantly enhanced cytotoxicity. This enhancement was inhibited by the addition of excess human immunoglobulins, suggesting that antibody-dependent cytotoxicity, mediated by activated NK cells in the CAK cell culture was involved in this mechanism. Conclusion: Cetuximab may be used to enhance CAK cell therapeutic activity in patients with cholangiocarcinoma, by potentiating antibody-dependent cellular cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=84864561428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864561428&partnerID=8YFLogxK

M3 - Article

C2 - 22641659

AN - SCOPUS:84864561428

VL - 32

SP - 2249

EP - 2256

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -